U.S. markets close in 4 hours 48 minutes

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
51.31-0.75 (-1.44%)
As of 4:57PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close52.06
Open52.12
Bid51.33 x 28400
Ask51.34 x 2100
Day's Range51.03 - 52.80
52 Week Range39.91 - 73.63
Volume2,175,814
Avg. Volume3,517,396
Market Cap50.408B
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-10.69
Earnings DateMay 12, 2021
Forward Dividend & Yield2.80 (5.35%)
Ex-Dividend DateApr 29, 2020
1y Target Est119.69
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Bayer flags lower earnings as agriculture arm disappoints
      Reuters

      Bayer flags lower earnings as agriculture arm disappoints

      Pharma and pesticides group Bayer's earnings guidance for this year fell short of investors' expectations on Thursday, raising questions about the strength of the agriculture business it boosted with the $63 billion takeover of Monsanto. Based on exchange rates at the end of 2020, Bayer said it expected 2021 adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of 10.5-10.8 billion euros ($12.8-$13.2 billion), down from 11.45 billion last year. Its shares were down 3.5% at 53.17 euros by 1300 GMT, erasing gains over the three previous trading sessions, as analysts said the lower-than-expected guidance pointed to a weaker seeds and pesticides unit.

    • Reuters

      FOCUS-Investors seed indoor farms as pandemic disrupts food supplies

      Investors used to brush off AminJadavji's pitch to buy Elevate Farms’ vertical growingtechnology and produce stacks of leafy greens indoors withartificial light. Now, indoor farms are positioning themselves as one of thesolutions to pandemic-induced disruptions to the harvesting,shipping, and sale of food. "It's helped us change the narrative," said Jadavji, whosecompany runs a vertical farm in Ontario, and is building othersin New York and New Zealand.

    • Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show
      Zacks

      Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show

      Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.